Attovia Therapeutics and Braveheart Bio revealed on Tuesday plans to go public, where they’ll aim to add to a recent upswing in big-ticket biotechnology stock offerings. 

Attovia was spun out of another drug company, Alamar Biosciences, in 2023 and has since brought to human testing an experimental treatment for a pair of itching conditions. That therapy, ATTO-1310, aims at IL-31, which the company claimed in regulatory filings to be known as the “itch cytokine.” It’s in Phase 1 testing in healthy volunteers as well as patients with chronic pruritis and “high-itch” atopic dermatitis. Attovia expects to begin a Phase 2 study by the first half of 2027.

Behind that prospect are two other drugs that could start their first human trials in 2027. ATTO-2306 goes after IL-31 and another well-known target, IL-13. ATTO-1091 simultaneously homes in on a trio of popular immune targets: TL1A, IL-23 and integrin a3B7. Attovia views the former as a potentially “differentiated” treatment for atopic dermatitis, and believes the later could improve upon existing treatments for inflammatory bowel disease. 

Attovia banked $256 million in private funding prior to its IPO filing. Its top investors include Frazier Life Sciences, Alamar, venBio, Goldman Sachs and Deep Track Capital. 

Braveheart, which is studying a drug for the progressive heart condition hypertrophic cardiomyopathy, also revealed plans to go public. It outlined the offering less than a year after banking a $185 million Series A round from Andreessen Horowitz and Forbion, among others, and is working on a treatment licensed from Hengrui Pharma. That deal was one of more than 100 cross-border pacts involving a China-based firm since the start of 2025, according to BioPharma Dive data.

Dubbed BHB‑1893, Braveheart’s medicine is designed similarly to cardiac myosin inhibitors like Bristol Myers Squibb’s Camzyos and Cytokinetics’ Myqorzo. But Braveheart believes certain attributes could give it “best-in-class” potential and allow for a simpler dosing regimen. 

Hengrui has already completed Phase 2 trials in both the “obstructive” and “non-obstructive” forms of hypertrophic cardiomyopathy, and has a Phase 3 study underway in obstructive disease in China. Braveheart intends to start global trials in both forms of the disease in late 2026 and early 2027, according to its IPO filing.

So far in 2026, 13 biotech companies have priced an IPO and raised a median of more than $300 million in the process, far more than what’s been seen in recent years. A majority are worth more than their debut share prices. And two other biotech startups, Scribe Therapeutics and Apnimed, have outlined IPO plans in July.

Should they go public, Attovia and Braveheart will sell shares under the respective ticker symbols “ATTO” and “BRVE.”